Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
VLP Therapeutics
Modality
gene_therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06736379CT.gov Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mouth Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vrp-Encapsulated Sarna Encoding Il-12 (this asset) | VLP Therapeutics | P1 | CC · 43 |
| Nivestim | Jonsson Comprehensive Cancer Center | P3 | BB |
| Calcium Phosphate | Impaqtt Foundation | P3 | BB |
| Carboplatin | Radiation Therapy Oncology Group | P3 | BB |
| Amifostine | Radiation Therapy Oncology Group | P3 | B |
| Cyclophosphamide | Jonsson Comprehensive Cancer Center | P2 | B |
| Etoposide | Jonsson Comprehensive Cancer Center | P2 | B |
| Isocyclophosphamide | Jonsson Comprehensive Cancer Center | P2 | B |
| Palifermin | Jonsson Comprehensive Cancer Center | P2 | B |
+4 more in the Mouth Disorder cohort
Other indications for Vrp-Encapsulated Sarna Encoding Il-12
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Oral Cavity Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vrp-Encapsulated Sarna Encoding Il-12 in Mouth Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vrp-encapsulated-sarna-encoding-il-12-mouth-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →